SCHIZOPHRENIA RESEARCH

THE OFFICIAL JOURNAL OF THE SCHIZOPHRENIA INTERNATIONAL RESEARCH SOCIETY

Vol. 93, Nos. 1–3 **CONTENTS** **July 2007**

Cited in: *Current Contents/Life Sciences, Current Contents/Clinical Medicine, EMBASE/Excerpta Medica, Psychological Abstracts, PsychINFO, PsychALERT, Index Medicus, SCOPUS*

Research papers

Anterior cingulate volumes in schizophrenia: A systematic review and a meta-analysis of MRI studies
M. Baiano, A. David, A. Versace, R. Churchill, M. Balestrieri and P. Brambilla 1

Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia
G. Bartzokis, P.H. Lu, K.H. Nuechterlein, M. Gitlin, C. Doi, N. Edwards, C. Lieu, L.L. Altshuler and J. Mintz 13

Reduced *N*-acetyl-aspartate levels in schizophrenia patients with a younger onset age: A single-voxel ^{1}H spectroscopy study
J.A. Stanley, M. Vemulapalli, J. Nutche, D.M. Montrose, J.A. Sweeney, J.W. Pettegrew, F.P. MacMaster and M.S. Keshavan 23

DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia
N. Buttner, S. Bhattacharyya, J. Walsh and F.M. Benes 33

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D_1 agonist, is safe and tolerated in patients with schizophrenia
M.S. George, C.E. Molnar, E.L. Grenesko, B. Anderson, Q. Mu, K. Johnson, Z. Nahas, M. Knable, P. Fernandes, J. Juncos, X. Huang, D.E. Nichols and R.B. Mailman 42

CNS 14-3-3ζ: Changes with sex but not psychiatric diagnoses or psychotropic drug treatment
B. Dean, S.A. Boer, A. Mackinnon and M. Berk 51

Association analysis of AKT1 and schizophrenia in a UK case control sample
N. Norton, H.J. Williams, S. Dwyer, L. Carroll, T. Peirce, V. Moskvina, R. Segurado, I. Nikolov, N.M. Williams, M. Ikeda, N. Iwata, M.J. Owen and M.C. O'Donovan 58

Abnormalities of cingulate gyrus neuroanatomy in schizophrenia
L. Wang, M. Hosakere, J.C.L. Trein, A. Miller, J.T. Ratnanather, D.M. Barch, P.A. Thompson, A. Qiu, M.H. Gado, M.I. Miller and J.G. Csernansky 66

Prefrontal–thalamic–cerebellar gray matter networks and executive functioning in schizophrenia
N. Rüsch, I. Spoletini, M. Wilke, P. Bria, M. Di Paola, F. Di Iulio, G. Martinotti, C. Caltagirone and G. Spalletta 79

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis
M. Strassnig, J. Miewald, M. Keshavan and R. Ganguli 90

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial
T. Baptista, N. Rangel, V. Fernández, E. Carrizo, Y. El Fakih, E. Uzcátegui, T. Galeazzi, M.A. Gutiérrez, M. Servigna, A. Dávila, M. Uzcátegui, A. Serrano, L. Connell, S. Beaulieu and E.A. de Baptista 99

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study
R. Zoccali, M.R. Muscatello, A. Bruno, R. Cambria, U. Micò, E. Spina and M. Meduri 109

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
M. Davidson, R. Emsley, M. Kramer, L. Ford, G. Pan, P. Lim and M. Eerdekens 117

Double-blind donepezil–placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study
S.C. Risch, M.D. Horner, S.R. McGurk, S. Palecko, J.S. Markowitz, Z. Nahas and C.L. DeVane 131

Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables
A.M. Meaney and V. O'Keane 136

Self-report of attenuated psychotic experiences in a college population
R.L. Loewy, J.K. Johnson and T.D. Cannon 144

Inconsistency in the relationship between duration of untreated psychosis (DUP) and negative symptoms: Sorting out the problem of heterogeneity
N. Schmitz, A. Malla, R. Norman, S. Archie and R. Zipursky 152

Remission in prognosis of functional outcome: A new dimension in the treatment of patients with psychotic disorders
L. Helldin, J.M. Kane, U. Karilampi, T. Norlander and T. Archer 160

Validity of a 'proxy' for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS)
R.R. Goetz, C. Corcoran, S. Yale, A.D. Stanford, D. Kimhy, X. Amador and D. Malaspina 169

The structure of psychosis revisited: The role of mood symptoms
M.P.M. Boks, S. Leask, J.K. Vermunt and R.S. Kahn 178

Heterogeneity in recovery of psychosocial functioning during psychiatric rehabilitation: An exploratory study using latent growth mixture modeling
J.E. Peer and W.D. Spaulding 186

A prospective study of Quality of life in schizophrenia in three European countries
D. Heider, M.C. Angermeyer, I. Winkler, G. Schomerus, P.E. Bebbington, T. Brugha, J.-M. Azorin and M. Toumi 194

(Contents continued on page 412)

0920-9964(200707)93:1-3;1-#

(contents continued from outside backcover)

A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis
J. Boydell, K. Dean, R. Dutta, E. Giouroukou, P. Fearon and R. Murray 203
Relevant dimensions of delusions: Continuing the continuum versus category debate
T.M. Lincoln 211
Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study
A. Mogg, R. Purvis, S. Eranti, F. Contell, J.P. Taylor, T. Nicholson, R.G. Brown and D.M. McLoughlin 221
The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on obstetric complications
L.M. Ellman, M. Huttunen, J. Lönnqvist and T.D. Cannon 229
Reduced posterior nasal cavity volume: A gender-specific neurodevelopmental abnormality in schizophrenia
B.I. Turetsky, C.A. Glass, J. Abbazia, C.G. Kohler, R.E. Gur and P.J. Moberg 237
Facial measurement differences between patients with schizophrenia and non-psychiatric controls
M.T. Compton, J. Brudno, A.D. Kryda, A.M. Bollini and E.F. Walker 245
Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure
D.E. Gard, A.M. Kring, M.G. Gard, W.P. Horan and M.F. Green 253
C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia
F. Dickerson, C. Stallings, A. Origoni, J. Boronow and R. Yolken 261
Neurocognitive deficits in the (putative) prodrome and first episode of psychosis
A.D. Eastvold, R.K. Heaton and K.S. Cadenhead 266
Metacognition within narratives of schizophrenia: Associations with multiple domains of neurocognition
P.H. Lysaker, G. Dimaggio, K.D. Buck, A. Carcione and G. Nicolò 278
Deficient attentional modulation of startle eyeblink is associated with symptom severity in the schizophrenia spectrum
E.A. Hazlett, M.J. Romero, M.M. Haznedar, A.S. New, K.E. Goldstein, R.E. Newmark, L.J. Siever and M.S. Buchsbaum 288
Probabilistic reversal learning impairments in schizophrenia: Further evidence of orbitofrontal dysfunction
J.A. Waltz and J.M. Gold 296
Quantifying incoherence in speech: An automated methodology and novel application to schizophrenia
B. Elvevåg, P.W. Foltz, D.R. Weinberger and T.E. Goldberg 304
Schizotypy versus openness and intelligence as predictors of creativity
G.F. Miller and I.R. Tal 317
Factor analytic support for social cognition as a separable cognitive domain in schizophrenia
D.N. Allen, G.P. Strauss, B. Donohue and D.P. van Kammen 325
Transcranial Magnetic Stimulation at M1 disrupts cognitive networks in schizophrenia
N. Levit-Binnun, N.Z. Handzy, E. Moses, I. Modai and A. Peled 334
Visuospatial memory deficits in adolescent onset schizophrenia
A. Vance, N. Hall, M. Casey, F. Karsz and M.A. Bellgrove 345
Ecological assessment of executive dysfunction in the psychosis prodrome: A pilot study
T.A. Niendam, J. Horwitz, C.E. Bearden and T.D. Cannon 350
Event related brain potential evidence for preserved *attentional* set switching in schizophrenia
P.D. Kieffaber, B.F. O'Donnell, A. Shekhar and W.P. Hetrick 355
P300 asymmetry and positive symptom severity: A study in the early stage of a first episode of psychosis
L. Renoult, M. Prévost, M. Brodeur, C. Lionnet, R. Joober, A. Malla and J.B. Debruille 366
Systematic study of association of four GABAergic genes: Glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, $GABA_B$ receptor 1 gene and $GABA_A$ receptor subunit β2 gene, with schizophrenia using a universal DNA microarray
X. Zhao, S. Qin, Y. Shi, A. Zhang, J. Zhang, L. Bian, C. Wan, G. Feng, N. Gu, G. Zhang, G. He and L. He 374
A Case-control association study between the *GRID1* gene and schizophrenia in the Chinese Northern Han population
S.-Z. Guo, K. Huang, Y.-Y. Shi, W. Tang, J. Zhou, G.-Y. Feng, S.-M. Zhu, H.-J. Liu, Y. Chen, X.-D. Sun and L. He 385
No association evidence between schizophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese families
C.-M. Liu, Y.-L. Liu, C.S.-J. Fann, W.-C. Yang, J.-Y. Wu, S.-I. Hung, W.J. Chen, C.-M. Chueh, W.-M. Liu, C.-C. Liu, M.-H. Hsieh, T.-J. Hwang, S.V. Faraone, M.T. Tsuang and H.-G. Hwu 391
Psychiatric morbidity and X-chromosomal origin in a Klinefelter sample
M.P.M. Boks, M.H.T. de Vette, I.E. Sommer, S. van Rijn, J.C. Giltay, H. Swaab and R.S. Kahn 399
Early-onset schizophrenia and obsessive–compulsive disorder in a young man with Dandy-Walker variant
G. Papazisis, A. Mastrogianni and A. Karastergiou 403

Letters to the Editors

Can fMRI-guidance improve the efficacy of rTMS treatment for auditory verbal hallucinations?
I.E.C. Sommer, A.D. de Weijer, K. Daalman, S.F. Neggers, M. Somers, R.S. Kahn, C.W. Slotema, J.D. Blom, H.W. Hoek and A. Aleman 406
Possible case of allopurinol causing relapse of psychosis
R. Gomberg 409
Risperidone-induced sialorrhea responsive to biperiden treatment
P.T. Panagiotidis, K.N. Fountoulakis, M. Siamouli, S. Magiria, A. Iacovides and G. Kaprinis 410